Benefits and harms of fibrate therapy in patients with type 2 diabetes: a systematic review and meta-analysis.

Rene Rodriguez-GutierrezMariana Garcia-LealKarina Raygoza-CortezAndrea Flores-RodríguezMarcela Moreno-AlvaradoE Maximiliano Heredia-MartínezBriana Vazquez-BaquerizoRaul Guerra-EspiricuetaValeria Muñoz-SilvaJose Gerardo Gonzalez-Gonzalez

Published in: Endocrine (2023)

Fibrate therapy in patients with T2D results in a marginal improvement of TGs and HDL-c but without reducing the risk of CV events and mortality. Their use should be reserved for very specific scenarios after a deliberative dialogue between patients and clinicians regarding their benefits and harms.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
palliative care
stem cells
type diabetes
risk factors
patient reported outcomes
mesenchymal stem cells
cell therapy